PF 4629991Alternative Names: PF-4629991
Latest Information Update: 28 Jan 2010
At a glance
- Originator Pfizer
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 27 Jan 2010 Discontinued - Phase-I for Rheumatoid arthritis in USA (unspecified route)
- 31 Mar 2009 Phase-I clinical trials in Rheumatoid arthritis in USA (unspecified route)